Shanghai Pulmonary Hospital

Institution (Healthcare)

Homepage ROR

Also Known As

Shanghai Pulmonary Hospital

7.7K

Publications

668.8K

Citations

517

Authors

667

Concepts

About

Shanghai Pulmonary Hospital is a healthcare institution in Shanghai, China known for medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	94	3.2K	198.9K
2	Engineering	49	414	27.6K
3	Health Sciences	48	572	29.3K
4	Natural Sciences	16	76	7.3K
5	Nursing	2	3	63

Shanghai Pulmonary Hospital

7.7K

Publications

668.8K

Citations

Page 1

	Year	Citations
TIMER2.0 for analysis of tumor-infiltrating immune cells Taiwen Li, Jingxin Fu, Zexian Zeng, Nucleic Acids Research	2020	5.5K
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, New England Journal of Medicine	2017	5K
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, New England Journal of Medicine	2019	2.7K
Expanded encyclopaedias of DNA elements in the human and mouse genomes Federico Abascal, Reyes Acosta, Nicholas J. Addleman, Nature	2020	2.4K
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi‐Long Wu, Caicun Zhou, Chengping Hu, The Lancet Oncology Lux-lung 6MedicineRandomised Phase 3PathologyBronchial Neoplasm	2014	2K
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, The Lancet Oncology Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm	2015	1.6K
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, The Lancet OncologyAdjuvant ChemotherapyPathologyImmune Checkpoint InhibitorCancer Treatment	2021	1.4K
TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment Dongqing Sun, Jin Wang, Ya Han, Nucleic Acids Research	2020	1.1K
Large-scale public data reuse to model immunotherapy response and resistance Jingxin Fu, Karen Li, Wubing Zhang, Genome Medicine	2020	1.1K

Page 1